Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2017

Detailed TOC of Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2017

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hyperphosphatemia In Chronic Kidney Disease - Overview
Hyperphosphatemia In Chronic Kidney Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hyperphosphatemia In Chronic Kidney Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hyperphosphatemia In Chronic Kidney Disease - Companies Involved in Therapeutics Development
3SBio Inc
Ardelyx Inc
Daiichi Sankyo Company Ltd
Medice Arzneimittel Putter GmbH & Co KG
OPKO Health Inc
PDX Pharmaceuticals LLC
Shield Therapeutics Plc
Spectrum Pharmaceuticals Inc
Toray Industries Inc
Hyperphosphatemia In Chronic Kidney Disease - Drug Profiles
DS-2330 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fermagate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
niacinamide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PDX-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PT-20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RDX-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sevelamer carbonate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia In CKD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target Phosphate for Hyperphosphatemia In Chronic Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPI-014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tenapanor hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRK-390 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VS-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects
Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products
Hyperphosphatemia In Chronic Kidney Disease - Product Development Milestones
Featured News & Press Releases
Jan 06, 2017: Shield Therapeutics Provides Update on PT20
May 07, 2015: Phosphate Therapeutics announces positive results in the PEACH pivotal study of its novel phosphate binder (PT20) for the treatment of hyperphosphatemia
Feb 02, 2015: Ardelyx Reports Results from Phase 2b Clinical Trial Evaluating Tenapanor in Treating Hyperphosphatemia in Chronic Kidney Disease Patients on Hemodialysis
Jan 07, 2013: Spectrum Pharma Announces Positive RenaZorb Phase I Clinical Data Demonstrating Robust Activity In Easy-to-swallow Pill Formulation
May 29, 2012: Spectrum Pharma Announces Enrollment Of First Group Of Patients In Phase I Clinical Trial Of RenaZorb
Dec 05, 2011: Spectrum Pharmaceuticals Files Investigational New Drug Application With FDA For SPI-014
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer